Endologix acquires medical device company focused on peripheral artery disease
Endologix, a California-based healthcare company, has acquired PQ Bypass, a technology company known for its treatments for severe peripheral artery disease. Terms of the deal have not been announced at this time.
PQ Bypass has gained significant attention for the development of its Detour platform, an investigational treatment for percutaneous femoral-popliteal bypass. The platform is currently being assessed by researchers in both the United States and Europe. It received the FDA’s breakthrough device designation in 2020.
“The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease,” Richard Mott, CEO and chairman Endologix, said in a statement. “We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals and patients, with a commitment to world-class medical education, clinical research and excellent procedural outcomes.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.